drugset / Trial / NCT01527513

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

NCT01527513

Phase 2 Completed 123 enrolled Bial - Portela C S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.

Timeline

Start
2010-08
Primary completion
2012-03
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 30 mg/kg Oral

Indications